The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Drug: Talquetamab
Talquetamab will be administered subcutaneously (SC).
Other Name: JNJ-64407564
Study Contact
844-434-4210
Participate-In-This-Study@its.jnj.com
Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC